Table 2.
Patient characteristics according to bleeding status.
| All | Bleeding (n = 32) | No bleeding (n = 28) | p-value | |
|---|---|---|---|---|
| Age, years | 63 (54–75) | 66 (55.75–71) | 58.5 (46.5–67.5) | 0.096 |
| Hb, g/dL | 9.6 (8.7–10.9) | 9.8 (9.0–11.47) | 9.3 (8.5–10.9) | 0.32 |
| Platelets, × 109/L | 117.0 (88.0–196.0) | 110 (90–182.25) | 130 (88–242) | 0.63 |
| γGT, U/L | 45.5 (29.25–89.25) | 47.5 (34.5–95.25) | 40.5 (21.25–87.25) | 0.29 |
| ALAT, U/L | 59.0 (29.25–89.25) | 69.0 (25.25–166.0) | 58.5 (26.25–271.0) | 0.79 |
| ASAT, U/L | 131.5 (40.75) | 102.0 (32.25–388.0) | 223.5 (55.25–585.75) | 0.34 |
| LDH, U/L | 616.0 (355.0–1,472.0) | 618 (331.0–2,382.0) | 590 (363.25–1,321.25) | 0.85 |
| avWS, n (%) | 31 (75.6) | 26 (92.9) | 5 (38.5) | < 0.001 |
| Uncontrolled, n (%) | 19 (31.7) | 4 (12.5) | 15 (53.6) | 0.001 |
| RC, n | 8.5 (0–22.25) | 17.0 (4.25–23.75) | 2.5 (0–11.0) | 0.005 |
| PC, n | 3 (1–6) | 4 (2–8.5) | 2 (0.5–5.0) | 0.056 |
| FFP, n | 5.5 (0–14.5) | 6 (3–20.5) | 0 (0–10) | 0.063 |
| ECMO, n (%) | 22 (36.7) | 13 (40.6) | 9 (32.1) | 0.49 |
| Access site bleeding, n (%) | 1 (1.7) | 1 (3.1) | 0 (0) | 1.0 |
Data are presented as number (%) or median (interquartile range).
γGT γ-glutamyl transferase, alanine aminotransferase; ASAT aspartate aminotransferase, LDH lactate dehydrogenase, avWS acquired von Willebrand syndrome, Uncontrolled patients missing extensive analyses, RC red cell concentrate, PC platelet concentrate, FFP fresh frozen plasma, ECMO extra corporal membrane oxygenation.